FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1591617358> ?p ?o ?g. }

• W1591617358 endingPage "115" @default.
• W1591617358 startingPage "109" @default.
• W1591617358 abstract "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Tofacitinib (CP‐690,550) is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease‐modifying therapy in rheumatoid arthritis. • Non‐renal elimination accounts for 70% of the total clearance of tofacitinib and the metabolism is primarily mediated by cytochrome P450 (CYP) 3A4. • This study was required to determine the effect of tofacitinib on the in vivo pharmacokinetics of a sensitive CYP3A4 substrate. WHAT THIS STUDY ADDS • The pharmacokinetics of midazolam, a sensitive CYP3A4 substrate, are not altered when co‐administered with tofacitinib in healthy subjects. • Tofacitinib is unlikely to affect the clearance of drugs metabolized by CYP enzymes. • There is no need for dose adjustments of CYP substrates when co‐administered with tofacitinib. AIMS To investigate inhibitive and inductive effects of tofacitinib (CP‐690,550), a Janus kinase inhibitor, on CYP3A4 function via in vitro and in vivo studies. METHODS In vitro experiments were conducted to assess the inhibition and induction potential of tofacitinib for major drug metabolizing enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4). A phase 1, randomized, open‐label, two‐way crossover study (NCT00902460) was conducted to confirm the lack of inhibitive/inductive effect on a sensitive CYP3A4 substrate, midazolam, in healthy subjects. Midazolam pharmacokinetics were assessed over 24 h following single dose 2 mg administration prior to administering tofacitinib and after twice daily dosing of tofacitinib 30 mg for 6 days. The primary endpoint was midazolam area under the concentration–time profile, from time 0 to infinity (AUC(0,∞)). RESULTS In vitro studies demonstrated low potential for CYP inhibition (I C 50 estimates tofacitinib >30 µ m ), CYP3A4 mRNA induction (observed at tofacitinib concentrations ≥25 µ m ) and no effect on enzymatic activity of CYP substrates. In the human study, AUC(0,∞) adjusted geometric mean ratio for midazolam plus tofacitinib to midazolam alone was 103.97% [90% confidence interval (CI) 95.57, 113.12], wholly within the pre‐specified acceptance region (80, 125). The 90% CI for the ratio of adjusted geometric means of maximum plasma concentration ( C max ) (95.98, 108.87) was also wholly within this acceptance region. CONCLUSIONS These data confirm a lack of an inhibitive or inductive effect of tofacitinib on CYP3A activity in humans and, in conjunction with in vitro data, support the conclusion that tofacitinib is unlikely to influence the CYP enzyme system as a whole." @default.
• W1591617358 created "2016-06-24" @default.
• W1591617358 creator A5003937993 @default.
• W1591617358 creator A5014602567 @default.
• W1591617358 creator A5025749465 @default.
• W1591617358 creator A5030758366 @default.
• W1591617358 creator A5033437999 @default.
• W1591617358 creator A5053704561 @default.
• W1591617358 creator A5054965158 @default.
• W1591617358 creator A5072429797 @default.
• W1591617358 date "2012-06-11" @default.
• W1591617358 modified "2023-10-17" @default.
• W1591617358 title "Lack of effect of tofacitinib (CP‐690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of <i>in vitro</i> data" @default.
• W1591617358 cites W1978470492 @default.
• W1591617358 cites W1985046754 @default.
• W1591617358 cites W1985984753 @default.
• W1591617358 cites W1993544887 @default.
• W1591617358 cites W2013096789 @default.
• W1591617358 cites W2016380386 @default.
• W1591617358 cites W2027410033 @default.
• W1591617358 cites W2048964610 @default.
• W1591617358 cites W2061785558 @default.
• W1591617358 cites W2074439189 @default.
• W1591617358 cites W2101217991 @default.
• W1591617358 cites W2149189075 @default.
• W1591617358 cites W2161976213 @default.
• W1591617358 cites W4232301166 @default.
• W1591617358 cites W4237298602 @default.
• W1591617358 doi "https://doi.org/10.1111/j.1365-2125.2012.04168.x" @default.
• W1591617358 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3394134" @default.
• W1591617358 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22233204" @default.
• W1591617358 hasPublicationYear "2012" @default.
• W1591617358 type Work @default.
• W1591617358 sameAs 1591617358 @default.
• W1591617358 citedByCount "31" @default.
• W1591617358 countsByYear W15916173582013 @default.
• W1591617358 countsByYear W15916173582014 @default.
• W1591617358 countsByYear W15916173582015 @default.
• W1591617358 countsByYear W15916173582016 @default.
• W1591617358 countsByYear W15916173582017 @default.
• W1591617358 countsByYear W15916173582018 @default.
• W1591617358 countsByYear W15916173582019 @default.
• W1591617358 countsByYear W15916173582020 @default.
• W1591617358 countsByYear W15916173582022 @default.
• W1591617358 crossrefType "journal-article" @default.
• W1591617358 hasAuthorship W1591617358A5003937993 @default.
• W1591617358 hasAuthorship W1591617358A5014602567 @default.
• W1591617358 hasAuthorship W1591617358A5025749465 @default.
• W1591617358 hasAuthorship W1591617358A5030758366 @default.
• W1591617358 hasAuthorship W1591617358A5033437999 @default.
• W1591617358 hasAuthorship W1591617358A5053704561 @default.
• W1591617358 hasAuthorship W1591617358A5054965158 @default.
• W1591617358 hasAuthorship W1591617358A5072429797 @default.
• W1591617358 hasBestOaLocation W15916173582 @default.
• W1591617358 hasConcept C109650736 @default.
• W1591617358 hasConcept C112705442 @default.
• W1591617358 hasConcept C126322002 @default.
• W1591617358 hasConcept C142724271 @default.
• W1591617358 hasConcept C185592680 @default.
• W1591617358 hasConcept C204787440 @default.
• W1591617358 hasConcept C27081682 @default.
• W1591617358 hasConcept C2776233030 @default.
• W1591617358 hasConcept C2777575956 @default.
• W1591617358 hasConcept C2778886723 @default.
• W1591617358 hasConcept C526171541 @default.
• W1591617358 hasConcept C62231903 @default.
• W1591617358 hasConcept C71924100 @default.
• W1591617358 hasConcept C87813604 @default.
• W1591617358 hasConcept C97320921 @default.
• W1591617358 hasConcept C98274493 @default.
• W1591617358 hasConceptScore W1591617358C109650736 @default.
• W1591617358 hasConceptScore W1591617358C112705442 @default.
• W1591617358 hasConceptScore W1591617358C126322002 @default.
• W1591617358 hasConceptScore W1591617358C142724271 @default.
• W1591617358 hasConceptScore W1591617358C185592680 @default.
• W1591617358 hasConceptScore W1591617358C204787440 @default.
• W1591617358 hasConceptScore W1591617358C27081682 @default.
• W1591617358 hasConceptScore W1591617358C2776233030 @default.
• W1591617358 hasConceptScore W1591617358C2777575956 @default.
• W1591617358 hasConceptScore W1591617358C2778886723 @default.
• W1591617358 hasConceptScore W1591617358C526171541 @default.
• W1591617358 hasConceptScore W1591617358C62231903 @default.
• W1591617358 hasConceptScore W1591617358C71924100 @default.
• W1591617358 hasConceptScore W1591617358C87813604 @default.
• W1591617358 hasConceptScore W1591617358C97320921 @default.
• W1591617358 hasConceptScore W1591617358C98274493 @default.
• W1591617358 hasIssue "1" @default.
• W1591617358 hasLocation W15916173581 @default.
• W1591617358 hasLocation W15916173582 @default.
• W1591617358 hasLocation W15916173583 @default.
• W1591617358 hasLocation W15916173584 @default.
• W1591617358 hasOpenAccess W1591617358 @default.
• W1591617358 hasPrimaryLocation W15916173581 @default.
• W1591617358 hasRelatedWork W1545824045 @default.
• W1591617358 hasRelatedWork W2113082323 @default.
• W1591617358 hasRelatedWork W2248533790 @default.
• W1591617358 hasRelatedWork W2605582956 @default.
• W1591617358 hasRelatedWork W2752345645 @default.

• next